Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other benefits. Antiretroviral ...
ATLANTA--(BUSINESS WIRE)--Mar. 5, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed 24-week results from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results